Inovio shares fall as AstraZeneca pares down partnership by Ben Adams Wednesday, May 29, 2019 AstraZeneca is starting to look at cutting some of the fat from its external pacts, and Inovio is in the crosshairs.
I-O startup Geneos raises $10.5M for neoantigen drugs by Phil Taylor Friday, February 22, 2019 Inovio spinout Geneos goes independent with a $10.5 million first-round financing for R&D in neoantigen-targeting cancer immunotherapies.
New discoveries in conception and breast cancer—News of Note by Arlene Weintraub Monday, October 15, 2018 New biotech discoveries include CRISPR-induced conception and a biomarker for predicting breast cancer recurrences.
Sensei hires new CMO as it eyes phase 2 immuno-oncology trial by Conor Hale Tuesday, August 21, 2018 Sensei Biotherapeutics named Ildiko Csiki as CMO. Csiki was previously VP of immuno-oncology clinical development at Inovio Pharmaceuticals.
Chutes & Ladders—Teva’s former chairman resigns amid layoffs by Angus Liu Friday, December 15, 2017 Teva’s former chairman Peterburg resigns, OrbiMed founder Isaly steps down, Grail poaches Roche exec Cook as CEO.
New ideas could boost Zika-targeted research by Amirah Al Idrus Friday, December 15, 2017 A Stanford team aimed at host cells to fight flaviviruses, while Harvard scientists examined the longevity of Zika vaccines.
DNA vaccine against Zika yields immune response in phase 1 trial by Arlene Weintraub Thursday, October 5, 2017 A synthetic DNA vaccine developed by the Wistar Institute and Penn scientists, with support from Inovio and GeneOne, shows promise in human trials.
One step closer to a Zika vaccine for pregnant women by Amirah Al Idrus Friday, July 14, 2017 A pair of experimental vaccines protected mouse fetuses from brain defects caused by Zika infection.
Chutes & Ladders—Allergan vet to replace Kaye as Sarepta’s CEO by Angus Liu Friday, June 30, 2017 Sarepta taps ex-Allergan leader Ingram as CEO, Biogen places Steele in corporate affairs role, Fikry will lead PPD's lab services.
Synthetic DNA vax protects 100% of animals susceptible to Zika by Amirah Al Idrus Thursday, November 10, 2016 For the first time, researchers have tested a Zika vaccine in animals that do not have a natural resistance to the virus. The synthetic DNA jab protected 100% of vaccinated animals from Zika infection, brain damage and death.
